GHK-Cu Month by Month: What Actually Happens in the First 3 Months

What the post-laser trial measured, and when

Randomized patients had skin around the mouth resurfaced with a CO2 laser, then used post-treatment skin care with or without GHK-Cu; 13 patients completed. Redness was evaluated throughout the post-treatment period using computer software and blinded evaluators. Wrinkles and overall skin appearance were assessed 12 weeks after treatment. Neither analysis found a significant difference between groups, and all patients improved. A patient questionnaire did show significantly greater improvement in overall skin quality with GHK-Cu (P=.04) [1]. The trial did not report results month by month.

The wound-healing trial

In a prospective randomized evaluator-blinded trial, 86 evaluable patients completed treatment of venous stasis ulcers. The 0.4% tripeptide copper complex cream was no different from an inert vehicle placebo on ulcer size, while silver sulfadiazine 1% reduced ulcer size [2].

Where the expected benefits come from

Collagen and proteoglycan stimulation, metalloproteinase modulation, attraction of immune and endothelial cells to injury, and faster wound healing in dogs, rats, mice and pigs come from laboratory and animal work summarized by the researchers who proposed those actions. These are preclinical or proposed mechanisms, not proven human effects [4]. That 2015 narrative review also reports cosmetic findings such as firmer skin and fewer fine lines, drawing largely on laboratory and company-type data rather than a randomized trial [4].

Hair: what was actually tested

The hair work cited here is ex vivo laboratory work with a related molecule. AHK-Cu, which has alanine in place of glycine, stimulated elongation of cultured human hair follicles at 10^-12 to 10^-9 M and promoted dermal papilla cell proliferation; at 10^-9 M it reduced apoptotic dermal papilla cells, though not significantly [8]. It is not GHK-Cu and not a human trial.

Safety and regulatory status

No FDA-approved drug contains GHK-Cu [5]. Topical copper peptide serums and creams are sold as cosmetics, which do not need FDA approval before sale; a product claiming to treat disease or change the body's structure or function is regulated as a drug [6]. No adverse-event rates for topical copper peptide products were found in the trials checked.

For injectable GHK-Cu, FDA lists the substance as nominated but withdrawn and states that compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [7]. Non-injectable GHK-Cu is in category 1 of FDA's interim compounding policy, and FDA plans to consult its Pharmacy Compounding Advisory Committee on the bulks list before the end of February 2027 [5][9].